In a moment that reveals how geopolitical conscience is reshaping institutional life, Britain's Royal College of Nursing has severed its commercial ties with Teva UK, the British arm of Israel's largest pharmaceutical company, following sustained advocacy from pro-Palestine campaign groups. The RCN, steward of professional values for more than half a million nurses, cited a decade of regulatory sanctions against Teva — including hundreds of millions in fines for anti-competitive behaviour, price-fixing, and international bribery — as incompatible with the ethical commitments the nursing profes
UK nursing union severs ties with Israeli drug firm over military links
Healthcare is at its best when it remains focused on patients rather than being politicised
Mark
So the RCN just decided to drop Teva as a sponsor. What actually triggered that?
Mimi
Campaign groups—Nurses for Palestine and another organization called UKHPRC—had been pushing them to end the relationship. The RCN then did what they called "further due diligence" and found that Teva's operations didn't align with nursing values.
Luke
But what does "further due diligence" mean exactly? Did they investigate something new, or were they already aware of Teva's fines and just needed political cover to act?
Mimi
The letter from the RCN chair mentions legal sanctions and public scrutiny, which matches Teva's actual track record—the EU fines, the US settlements. So it seems they looked at what was already documented.
Mark
And Teva's response was basically to say healthcare shouldn't be political?
Mimi
Yes. They said they're disappointed and that healthcare works best when focused on patients, not politics. They also emphasized they're one of the NHS's biggest medicine suppliers.
Luke
That's a fair point though, isn't it? The RCN's decision is explicitly political—it's about Israel, not about whether Teva's drugs are safe or effective for NHS patients.
Mimi
True. But the RCN framed it around corporate misconduct—the bribery, the price-fixing, the blocking of competitors. Those are real things that happened.
Mark
So is the concern about Israel, or about Teva's business practices?
Luke
The source material shows both. The campaign groups mention Israel's military and international law violations. The RCN letter mentions legal sanctions and corporate track record. They're not entirely separable in how the groups are framing this.
Mimi
And now the same groups are targeting the Royal College of Pharmacy. So this isn't just about one decision—it's part of a broader push.
Mark
What happens if other professional bodies start doing the same thing?
Luke
That's the question. We don't know yet whether this becomes a pattern or remains isolated to the RCN.
The Pulse
- Campaign groups Nurses for Palestine and UK Healthcare Petitions to Royal Colleges applied sustained pressure on the RCN, forcing a formal review of a commercial relationship that had previously gone unquestioned.
- Teva's corporate record — €462.6m in EU fines for blocking MS drug competition, $225m in US price-fixing penalties, and $519m in bribery settlements — gave the RCN concrete ethical grounds beyond the political pressure alone.
- Teva pushed back, warning that healthcare is being weaponised as a political arena and stressing its role as one of the NHS's largest medicine suppliers, framing the rupture as damaging to patients rather than corporations.
- The RCN confirmed the split in writing, cancelling Teva's sponsorship of a migraine services event while allowing the event itself to proceed — a careful line between institutional principle and practical continuity.
- Campaign groups are already pivoting to the Royal College of Pharmacy, demanding it drop Teva from its upcoming annual conference, signalling that the RCN decision is the opening move in a coordinated institutional campaign.
In a moment that reveals how geopolitical conscience is reshaping institutional life, Britain's Royal College of Nursing has severed its commercial ties with Teva UK, the British arm of Israel's largest pharmaceutical company, following sustained advocacy from pro-Palestine campaign groups. The RCN, steward of professional values for more than half a million nurses, cited a decade of regulatory sanctions against Teva — including hundreds of millions in fines for anti-competitive behaviour, price-fixing, and international bribery — as incompatible with the ethical commitments the nursing profession claims to embody. What unfolds here is not merely a sponsorship dispute but a wider reckoning with the question of whose hands may legitimately touch the institutions of healing.
Britain's Royal College of Nursing has ended its commercial partnership with Teva UK, the British subsidiary of Israeli pharmaceutical giant Teva Pharmaceuticals, after sustained pressure from Nurses for Palestine and UK Healthcare Petitions to Royal Colleges. Teva had been set to sponsor a migraine and headache services event at the RCN's London headquarters on October 30, 2026; that event will now go ahead without the company's backing.
RCN council chair Carmel O'Boyle confirmed the decision in a letter to Nurses for Palestine, stating that further due diligence had uncovered operations within Teva that had faced legal sanctions and public scrutiny incompatible with the values the nursing profession upholds. The RCN, she wrote, was committed to commercial relationships only with companies whose practices met the profession's ethical standards.
Teva's recent corporate history lent the decision considerable weight beyond the political pressure. In 2024, the European Commission fined the company €462.6 million for blocking generic competitors from challenging its multiple sclerosis drug Copaxone across seven European countries. In 2023, Teva paid $225 million to the US Department of Justice to resolve price-fixing charges on three drugs. And in 2016, the company paid $519 million to settle criminal and civil bribery charges involving government officials in Russia, Ukraine, and Mexico.
Teva responded with disappointment, arguing that healthcare should not become a political battleground, and pointed to its status as one of the NHS's largest medicine suppliers. The company said it was seeking further dialogue with the RCN.
Campaign groups welcomed the move but immediately turned their attention elsewhere. The Royal College of Pharmacy is now being called upon to drop Teva as a sponsor of its own annual conference the following month — a sign that what began as pressure on one institution has become the opening move in a broader effort to disentangle Israeli-linked companies from British healthcare's professional infrastructure.
The Royal College of Nursing, which represents more than 500,000 nurses across the UK, has ended its commercial partnership with Teva UK, the British subsidiary of the Israeli pharmaceutical giant Teva Pharmaceuticals. The decision came after sustained pressure from campaign groups Nurses for Palestine and UK Healthcare Petitions to Royal Colleges, and it means Teva will no longer sponsor a migraine and headache services event scheduled for October 30, 2026, at the union's London headquarters. The event itself will proceed without the company's backing.
Carmel O'Boyle, chair of the RCN's ruling council, confirmed the move in a letter to Nurses for Palestine. She stated that further due diligence had revealed operations within Teva Pharmaceuticals that had faced legal sanctions and public scrutiny, and that these operations were incompatible with the values the nursing union claims to uphold. The RCN, she wrote, was committed to entering commercial relationships only with companies whose practices aligned with the nursing profession's ethical standards.
Teva responded by expressing disappointment and arguing that healthcare should not become a political arena. A company spokesperson emphasized Teva's role as one of the largest medicine suppliers to the NHS and said the firm was seeking further dialogue with the RCN. The company framed the decision as an unwelcome politicization of healthcare.
The pharmaceutical firm's corporate history provides context for the RCN's action. Over the past decade, Teva has accumulated substantial financial penalties from regulatory authorities on both sides of the Atlantic. In 2024, the European Commission fined the company €462.6 million for blocking competitors from offering Copaxone, its multiple sclerosis treatment, across seven European countries for periods ranging from four to nine years. In 2023, Teva agreed to pay $225 million to the US Department of Justice to avoid prosecution after being charged with price-fixing on three drugs. And in 2016, the company settled civil and criminal charges involving bribery of government officials in Russia, Ukraine, and Mexico by paying $519 million to US authorities.
Nurses for Palestine welcomed the RCN's decision, stating that a company with Teva's record had no place sponsoring professional bodies dedicated to healing and preserving life. UK Healthcare Petitions to Royal Colleges went further, calling it unconscionable for healthcare organizations to maintain commercial ties with firms linked to state systems accused by international bodies of grave violations of international law, including crimes against humanity, apartheid, and genocide.
The RCN's move signals a shift in how major professional bodies in Britain are approaching partnerships with Israeli-linked companies. Campaign groups are already turning their attention to the Royal College of Pharmacy, calling on it to drop Teva as a sponsor of its annual conference scheduled for the following month and to cancel the exhibition stand the company had booked. What began as pressure on one institution now appears to be the opening move in a broader effort to isolate Israeli-linked firms from British healthcare's institutional infrastructure.
Notable Quotes
We are taking this action because further due diligence showed that there are a number of Teva Pharmaceuticals' operations, which have been the subject of legal sanction and public scrutiny, which are not in line with RCNi and RCN values.— Carmel O'Boyle, chair of the RCN's ruling council
Teva has no place sponsoring professional bodies dedicated to healing, care and preserving human life.— Nurses for Palestine spokesperson
Want the full story?
Read the original at The Guardian ↗